Brainstorm Cell Therapeutics Inc. (BCLI)
BCLI is quoted over the counter, not listed on an exchange. Brainstorm Cell Therapeutics Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-16.
Profile
| Field | Value |
|---|---|
| Ticker | BCLI, quoted over the counter |
| SEC CIK | 0001137883 |
| OTC Markets tier | OTCQB (price source, 2026-11-13) |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Business address | New York, NY |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-14 |
| Cash and burn | $22K cash; operating cash flow -$1.0M a quarter. | Report 2026-06-30 |
| Shares outstanding | 11,034,775 (2026-08-11); 10,376,109 a year earlier; 45,015,800 three years earlier. 3y figure adjusted for splits (1-for-15 overall). | Cover page 2026-08-11 |
| Reverse splits, 3 years | 1; latest 1-for-15 on 2024-10-01 | Source 2024-10-01 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2025-10-09 |
| Auditor | Brightman Almagor Zohar & Co., Tel Aviv, Israel | PCAOB Form AP 2026-05-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$3.9M | -$895K | $22K | $1.3M | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$2.1M | -$1.3M | $15K | $1.3M | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2025 2025-12-31 | Not filed | -$2.4M | -$740K | $29K | $967K | Needs four quarters | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | Not filed | -$2.1M | -$1.1M | $5K | $101K | Needs four quarters | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | Not filed | -$2.9M | -$3.5M | $824K | $101K | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$2.9M | -$1.6M | $1.6M | $1.2M | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2024 2024-12-31 | Not filed | -$3.0M | -$1.0M | $187K | $300K | Needs four quarters | 10-K 2026-03-31 |
| Q3 2024 2024-09-30 | Not filed | -$2.7M | -$3.3M | $168K | No debt tags | Needs four quarters | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-1 | 2026-05-21 |
| Latest annual report | 10-K | 2026-03-31 |
| Latest quarterly / interim | 10-Q | 2026-08-14 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2025-05-16 |
Source: SEC EDGAR submissions feed, 950 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier